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Genomic alterations may make cancer cells more
dependent than normal cells on mechanisms of
proteostasis, including protein folding and degradation.
This proposition is the basis for the clinical use of
proteasome inhibitors to treat multiple myeloma and
mantle cell lymphoma. However, proteasome inhibitors
have not proved effective in treating other cancers, and
this has called into question the general applicability
of this approach. Here, I consider possible explanations
for this apparently limited applicability, and discuss
whether inhibiting other broadly acting components
of the ubiquitin-proteasome system - including
ubiquitin-activating enzyme and the AAA-ATPase
p97/VCP - might be more generally effective in
cancer therapy.copies [5,6]. This is particularly a problem for proteinsThe ubiquitin-proteasome system and the
‘proteotoxic crisis’ approach to cancer therapy
The ubiquitin-proteasome system (UPS) is the major
mechanism by which proteins are degraded in the cyto-
plasm and nucleus of eukaryotic cells and as such is a key
player in maintaining protein homeostasis [1]. Proteins
destined to be degraded by the UPS are tagged for de-
struction by conjugation to the small protein ubiquitin
through the action of ubiquitin-conjugating (E2) and ubi-
quitin ligase (E3) enzymes, which can result in the assem-
bly of ubiquitin chains on one or more lysine residues
within the substrate. Proteins modified with an ubiquitin
chain bind to ubiquitin receptors that link them to the
26S proteasome. The 26S proteasome is a large proteolytic
complex that degrades ubiquitin-modified proteins and
recycles the ubiquitin for future use.
Several lines of evidence suggest that cancer cells
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unless otherwise stated.homeostasis (proteostasis) [2], including the UPS (Figure 1).
Genome sequencing has revealed that cancer genomes
are typically littered with dozens to hundreds of point
mutations in protein coding sequences [3]. Many of these
mutated proteins are likely to present significant folding
challenges, with increased degradation of the mutant pro-
tein via the UPS being one possible outcome. In addition,
cancer cell genomes often contain large duplications, dele-
tions, inversions, and translocations as well as altered copy
numbers of entire chromosomes (aneuploidy). It has
been estimated that over 90% of human solid tumors
contain cells with more than two copies of one or more
chromosomes [4]. These excess chromosomes continue to
be expressed, and therefore protein synthesis in aneuploid
cancer cells is often imbalanced, with proteins encoded by
extra chromosomes being produced in excess over pro-
teins encoded by chromosomes that are present in two
that assemble to form stoichiometric complexes like the
ribosome. In such cases, the excess proteins almost cer-
tainly cannot attain stable conformations, and hence are
degraded by the UPS [7,8]. In theory, this creates in cancer
cells a heightened dependence on protein quality-control
(PQC) mechanisms, including protein chaperones, the
UPS, and autophagy [9-12]. In agreement with this,
approximately one-third of single chromosomal aneu-
ploidies in yeast cells render them hypersensitive to
proteasome inhibitors [13], and some yeast cells that
adapted to aneuploidy were found to contain muta-
tions that derepress the UPS [6]. These data suggest
that agents that inhibit PQC pathways should be more
toxic to cancer cells than normal cells, and might be used
to treat a broad variety of cancers. In the remainder of this
review, I will refer to this idea as the ‘proteotoxic crisis’
approach to cancer therapy. Here, I will focus on tar-
geting PQC pathways of the UPS as a means to induce
proteotoxic crisis in cancer cells. Other reviews have fo-
cused specifically on targeting chaperones or autophagy as
a means to treat cancer [11,12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1. Proteotoxic crisis in cancer cells. (A) In normal cells, the natural load of degradation substrates on the left is in balance with the
capacity of the cellular ubiquitin-proteasome system (UPS), signified by the proteasome on the right. (B) In cancer cells, the load is increased due
to expression of mutant proteins and/or expression of excess proteins due to aneuploidy. This results in an imbalance where the degradation
load exceeds the capacity of the UPS.
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hypothesis but raises questions about its
generality
The proteasome inhibitor bortezomib provided the first
direct evidence that it is possible to inhibit the UPS in a
manner that is lethal to at least some cancer cells while
mostly sparing normal cells [14]. Before discussing bor-
tezomib in detail, a primer on the structure and mech-
anism of the 26S proteasome is in order.
The catalytic core of the proteasome is a 20S cylinder,
the inside of which contains two copies each of the ac-
tive sites β1, β2, and β5 (Figure 2) [15]. A second form
of the proteasome, referred to as the immunoproteasome,
is enriched in cells of the hematopoietic lineage and has a
specialized function in immune cells, but an essentially
analogous composition in which the β1, β2, and β5 sites
are replaced by the closely related β1i, β2i, and β5i sites.
The β5/β5i sites (also known as the chymotrypsin-like
sites) are inhibited by bortezomib with high potency,
whereas the β1 (caspase-like) sites have approximately
10-fold lower affinity and the β2 sites are not appre-
ciably targeted under normal conditions [16-18]. Substrates
enter the 20S cylinder through its ends, which are capped
with structures referred to as 19S regulatory particles
(RPs). A 20S cylinder capped at each end with a 19S RP is
referred to as the 26S proteasome. Assembly of the 26S
proteasome is enabled by pockets at the ends of the 20S
cylinder into which are inserted short carboxy-terminal
tails that emanate from a heterohexameric ring of Rpt1-6
subunits in the 19S RP. Degradation substrates are teth-
ered to the 26S proteasome via their ubiquitin chain,
which binds to one or more of a set of receptor proteins,
some of which (for example, Rpn10 and Rpn13) are in-
trinsic to the 19S RP, while others (for example, hRad23,
hPLIC) shuttle on and off.It is thought that substrates are bound to the 26S pro-
teasome in a manner that enables them to be grasped by
the Rpt1-6 proteins, which are AAA ATPases that use
the energy derived from ATP hydrolysis to unfold sub-
strates, open the normally closed gate at the end of the
20S cylinder to admit substrate, and translocate the sub-
strate through a pore in the center of the Rpt ring and
into the internal chamber of the 20S cylinder. As sub-
strate is being translocated through the Rpt ring, the
Rpn11 subunit of the 19S RP, which is positioned immedi-
ately above the channel through the Rpt ring, scans for
ubiquitin chains. Rpn11 is a protease that removes ubiqui-
tin chains as the substrate translocates by, which is thought
to prevent the chains from clogging up the entry channel
into the proteasome.
Inhibition of 20S peptidase activity with bortezomib is
highly cytotoxic to the plasma cell cancer multiple mye-
loma (MM) [20], and bortezomib has been an effective
therapy for treating patients with this disease as well as
mantle cell lymphoma (MCL) [21-23]. However, despite its
considerable success as a therapy for MM and MCL, bor-
tezomib has not been approved for treating other cancers.
This is not for lack of effort: over 700 bortezomib trials
have or are being run [24], including many in indications
other than MM and MCL, in attempts to identify cancers
that might respond favorably. This clinical experience is
consistent with in vitro data: although brief exposure to
proteasome inhibitors is highly cytotoxic to MM cells, it is
not more cytotoxic to solid tumor cell lines than it is to
non-transformed cells [25]. These data raise an obvious
question - why aren’t proteasome inhibitors more broadly
effective as cancer therapeutics - and pose a serious chal-
lenge to the generality of the proteotoxic crisis hypothesis.
Most attempts to explain why proteasome inhibitors
work in MM and MCL but not in other cancers have
Figure 2. Structure of the 26S proteasome. The 20S core of the
proteasome is shown in grey. One copy of each of the β1, β2, and
β5 active sites is present within each of two seven-subunit rings
(the positions of which are marked with dashed blue lines) and face
towards the inside of the 20S chamber. Each end of the 20S core is
capped with a 19S regulatory particle, shown in various colors. The
Rpt1-6 ATPase ring that abuts the 20S core is shown in blue and
Rpn11 in green. Rpn10 (purple) and Rpn13 (gold) are two intrinsic
ubiquitin chain-binding receptors within the 26S proteasome.
The pore in the ATPase ring through which the substrate passes
is indicated. Electron density within the image that corresponds
to substrate is shown in red. Adapted from [19].
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level of activity of the pro-survival transcription factor
NF-κB [26]. Indeed, genomic and transcriptomic analyses
have revealed recurrent alterations in MM cells that de-
regulate NF-κB [27-29]. Proteasome inhibitors block deg-
radation of the NF-κB inhibitor IκB by the proteasome,
thereby inhibiting inducible NF-κB activity [30]. This could
explain why MM cells, particularly those accustomed to ahigh level of constitutive NF-κB activity, might be sensitive
to bortezomib. However, this is unlikely to be the key
mechanism of action, because an inhibitor of the IκB
kinase IKK (which is also required for IκB degrad-
ation) is not as effective as bortezomib at killing MM
cells [31]. Moreover, bortezomib does not downregu-
late NF-κB activity in primary MCL and MM cells or
in MM xenografts [32,33].
An additional explanation for the sensitivity of MM
cells to bortezomib is that they exhibit a lower threshold
for induction of a lethal ‘unfolded protein response’ (UPR)
[34]. The UPR is a homeostatic response that is mobilized
by the presence of unfolded proteins in the lumen of the
endoplasmic reticulum (ER) [35]. Under normal condi-
tions, these unfolded proteins are retrotranslocated back
to the cytosol, where they are degraded by the proteasome
in a process known as ER-associated degradation (ERAD)
[36]. However, when the burden of unfolded proteins in
the ER lumen is high, activation of the UPR enables cells
to cope with this problem by inhibiting protein synthesis
to reduce the load on the ER while upregulating genes to
enhance the biogenic capacity of the ER [35]. However,
sustained UPR signaling can eventually commit a cell to
apoptosis. Inhibition of the proteasome can activate an
apoptotic UPR in myeloma cells [34], presumably by inter-
fering with ERAD. MM plasma cells may be particularly
prone to a cytotoxic UPR because of their physiological
role in producing large quantities of antibody [37,38]. This
perches the cells on the edge of proteotoxic crisis, and
transient inhibition of the proteasome is the nudge that
pushes them into the abyss. Exposure to proteasome
inhibitors for as little as one hour can suffice to consign
MM plasma cells to an apoptotic fate, whereas much
higher levels of drug or longer exposures are normally
required to induce cell death in solid tumor cells [25]
and possibly in MM stem cells that are at an earlier
developmental stage [38]. Notably, cancer cells iso-
lated from MCL patients dosed with bortezomib do
not exhibit a strong UPR but instead show evidence
of NRF2 activation, suggesting that MM and MCL
may respond to bortezomib therapy for different rea-
sons [39]. A deeper understanding of why some MCL
patients respond to bortezomib could suggest other can-
cers that may be prone to respond to proteasome inhib-
ition in mono- or combination therapy.
If the proteotoxic crisis hypothesis is correct, it should
be possible to identify cancer types and treatment re-
gimes for which there is a favorable therapeutic index
for killing tumor cells with mutation-riddled genomes
while sparing normal cells. One place to start looking is
in cancers that originate in secretory tissues, including
neuroendocrine tumors in general and insulinoma in
particular. However, the search need not be limited to
‘secretory’ tumors. Indeed, it was recently argued that
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be generalized to a simple metric comprising the rate of
degradation of newly synthesized proteins (which is a
crude measure of PQC) divided by the level of prote-
asome activity [40,41]. Using this metric, which is more
broadly focused on PQC and does not necessarily invoke
a unique role for ERAD or UPR, it may be possible to
identify other cancers that are likely to be responsive to
proteasome inhibition.
Is the clinical action of bortezomib limited by
pharmacokinetics?
To understand why bortezomib has not been an effective
therapy for solid tumors and does not cure MM, it may
be useful to consider not only the physiology, but also
the pharmacology of proteasome inhibition. In general,
although it is usually possible to kill solid tumor cells
with bortezomib upon continuous exposure in plastic
dishes without too much difficulty, it can be much more
challenging to do so in mice. Among the numerous dif-
ferences between these two venues, it may be particu-
larly important to pay attention to pharmacokinetics.
Following its injection, bortezomib is quickly cleared
from human plasma [42]. In effect, injecting a human
with bortezomib is akin to doing a pulse-chase experi-
ment. Cells transiently exposed to bortezomib eventually
recover proteasome activity, both because bortezomib
dissociates from β5 (albeit slowly, with a t1/2 of 110 mi-
nutes [43]), and because inhibition of the proteasome
sets in motion a homeostatic mechanism (described in
more detail later in this review) that results in elevated
transcription of genes that encode proteasome subunits
[44,45]. Consequently, β5 inhibition follows a sawtooth
pattern in vivo (Figure 3A), with rapid inhibition of its
activity, followed by a slower recovery driven by drug
dissociation with a possible contribution by new prote-
asome synthesis. As a result, cells experience maximum
proteasome inhibition - the point of the sawtooth - for
only a few hours [46].
When injected at its standard clinical dose (1.3 mg/m2),
bortezomib elicits approximately 65% inhibition of β5 ac-
tivity in whole blood lysate at the point of the sawtooth
[47]. Importantly, biochemical studies suggest that inhib-
ition of β5 is likely to be insufficient, and co-inhibition of
the β1 site, which is 10-fold less sensitive to bortezomib
than β5, is required to prevent protein breakdown [18].
Furthermore, whole blood β5 activity is more sensitive to
bortezomib than solid tissues. At its maximum tolerated
dose in mice, bortezomib inhibits β5 activity to approxi-
mately 90% in whole blood, but only approximately
75% in the adrenal gland and 50% in a myeloma cell
xenograft [25]. A very recent study reported that fol-
lowing a 1 hour pulse treatment with 100 nM bortezomib
(which exceeds by two-fold the concentration achievedfollowing a subcutaneous dose), β5 activity was eliminated
but proteasome-dependent proteolysis was inhibited by
only 23 to 55% across seven MM cell lines and >70% cell
death was observed in only one of the lines [41]. This
study suggests that the degree of proteasome (as opposed
to β5) inhibition elicited by bortezomib in tumor tissue
in vivo - which has not been reported - is likely to be quite
modest. Perhaps the depth and duration of proteasome
suppression achieved in vivo is sufficient to kill MM
plasma cells teetering on the edge of UPR-dependent
apoptosis (Figure 3B), but not strong and long enough
to kill MM stem cells and most solid tumor cells, in-
cluding those that may have a heightened dependency
on the UPS.
If this idea is correct, it suggests that it might be pos-
sible to expand the range of cancers in which prote-
asome inhibitor therapy is effective by increasing the
extent of inhibition and reducing the rate at which pro-
teasome activity recovers following inhibition. This idea
was part of the motivation underlying the partnership
that Craig Crews and I formed to co-found Proteolix. The
Crews lab had discovered that the natural product epoxo-
micin is a covalent, irreversible inhibitor of the same β5
active site of the proteasome that is inhibited by bortezo-
mib [48]. They then went on to develop YU101, which is a
modified form of epoxomicin that is more specific for the
β5 site than the parent molecule [49]. We reasoned that
greater specificity might allow for a better tolerability pro-
file than bortezomib and hence the potential to achieve
stronger inhibition, whereas irreversibility would result in
a longer duration of proteasome inhibition because the
only way to recover activity would be to synthesize new
proteasome. Proteolix modified YU101 to generate carfil-
zomib [25], which has emerged as a successful second-
generation proteasome inhibitor drug. Carfilzomib, like
bortezomib, is an injectable drug that is cleared rapidly
from plasma [50]. Nevertheless, it has shown efficacy in
relapsed and refractory MM patients [51] and has shown
very promising activity in earlier stage myeloma patients
in combination with lenalidomide plus dexamethasone
[52]. By contrast, limited activity was observed in a phase
I/II study that included four different solid tumor types
[53]. However, as of October 2014 there are 63 open clin-
ical trials involving carfilzomib listed on clinicaltrials.gov
[54], including in kidney, prostate, lung, and ovarian
cancer, and so the jury is still out. Interestingly, des-
pite carfilzomib’s irreversibility, the rate of recovery of
proteasome β5 activity in tissues other than whole
blood following carfilzomib administration in mice is
not very much slower than that observed with borte-
zomib [25]. Thus, synthesis of new proteasomes appears
to be a powerful homeostatic mechanism that minimizes
the duration of proteasome inhibition following a pulse of
bortezomib or carfilzomib.
Figure 3. The sawtooth pattern of β5 inhibition in vivo and its relationship to the kinetics of cancer cell death. (A) A patient dosed with
bortezomib at the beginning of day 1 experiences approximately 65% inhibition of β5 activity (shown as a red trace) in whole blood lysate. β5
activity recovers, and the patient is dosed again on day 4. (B) Zoom-in of (A) to emphasize β5’s pharmacodynamic response to a single dose. In
this and the following examples, it is assumed that the kinetics of cancer cell death are a function of cell type and percentage inhibition. The
example shown assumes that MM cells commit to cell death within a few hours when the proteasome is inhibited by more than 60% (>60% I),
as signified by the time interval denoted by the light gray bar. On the other hand, solid tumor cells require much longer exposure (dark gray bar)
to effect cell death at 60% inhibition. (C) Same as (B), except that a greater percentage inhibition of the proteasome is achieved. Even though
the rate of recovery is the same as (B), it is suggested that solid tumor cells remain in the ‘kill zone’ below the dotted line sufficiently long to
commit to apoptosis. Note that even though the time required for killing solid tumors (dark gray bar) is drawn the same as in (B), a greater
percentage inhibition could reduce the time required to commit to apoptosis. (D) Same as (B), except the recovery curve has a shallower slope
due to inhibition of new proteasome synthesis. In this hypothetical example, reducing the rate of recovery maintains proteasome inhibition in
the ‘kill zone’ for a sufficiently long time to kill solid tumor cells.
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cancer cells are vulnerable because of their
heightened dependency on protein quality control
In light of the experience with bortezomib and carfilzomib,
is the proteotoxic crisis hypothesis likely to be generally
applicable beyond MM and MCL? Given the challenge of
establishing and maintaining a high level of PQC inhibition
in tumors with bortezomib and carfilzomib, it is difficult to
answer this question definitively. Answering it will require
the development of new agents that allow for more potent
and durable suppression of key PQC pathways in tumors.
There are five strategies for moving forward. The first,
which is somewhat counterintuitive, is to develop inhibi-
tors with faster off-rates. It has recently been shown that
ixazomib/MLN9708, an oral analog of bortezomib that is
undergoing clinical evaluation, has a much more rapid off-
rate from β5. Paradoxically, mice treated with this com-
pound exhibit stronger inhibition of proteasome activity in
xenografted tumors compared to mice treated with borte-
zomib [43]. This leads to a stronger anti-tumor effect, in-
cluding responses in xenograft models that are minimally
responsive to bortezomib. The authors propose that thehigh concentration of blood proteasome coupled with the
extremely slow off-rate of bortezomib limits its access to
peripheral tissues, which in turn may limit its effectiveness
(Figure 4A). Presumably, the same issue may apply to car-
filzomib. In effect, red blood cell proteasomes serve as a
sponge, diminishing access of proteasome inhibitors to
other tissues, including solid tumors. The high off-rate of
ixazomib allows it to more efficiently equilibrate through-
out the body (Figure 4B).
A second approach, which is also already underway, is
to develop oral proteasome inhibitors that would allow
for more flexibility in dosing. Ixazomib and oprozomib
are oral analogs of bortezomib and carfilzomib, respect-
ively, that are in mid- to late stage clinical development
as therapies for MM. As noted above, current therapy
with bortezomib and carfilzomib results in a sawtooth
pattern of β5 inhibition (Figure 3A). Is it possible that
maintaining a more constant level of inhibition for a
longer duration via repetitive oral dosing (Figure 4C)
might enable killing of solid tumor cells while sparing
normal cells? It is difficult to test this hypothesis with in-
jectable agents like bortezomib and carfilzomib because
Figure 4. Alternative strategies for testing the proteotoxic crisis hypothesis through proteasome inhibition. (A) Bortezomib (BTZ; red
asterisk) has a very slow off-rate from 26S proteasome (26S; gray cylinders). Coupled with the high concentrations of proteasomes in red blood
cells (RBCs), this results in sequestration of most BTZ in the RBC compartment following intravenous injection. (B) MLN9708 (purple asterisk)
dissociates from proteasome six-fold faster than BTZ, enabling better equilibration throughout the body and stronger inhibition of proteasome
in tumors. (C) Hypothetical pharmacodynamic response of β5 activity (red trace) in a patient repeatedly dosed (blue arrows) with an oral
proteasome inhibitor during the course of a single day. Repeat dosing may suffice to keep β5 activity in the ‘kill zone’ (in this example, >60%
inhibition) for a sufficiently long time interval (denoted by dark gray bar) to kill solid tumor cells. (D) Alternative drug targets in the proteasome: the
Rpt1-6 ATPase, Rpn11, and the pockets in 29S outer rings that serve as docking sites for Rpt ATPases in 19S regulatory particle.
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but this approach could be accessible with oral agents,
provided that they are tolerated by the gastrointestinal
tract.
A third approach, related to the one described above,
is to develop oral agents that target other aspects of
proteasome function (Figure 4D). The proteasome is
an extremely complex enzyme comprising multiple sub-
complexes each of which has enzymatic sites that are es-
sential for proteasome activity. There is a great deal of
precedent indicating that agents that hit the same target
but do so with a different molecular scaffold or by a differ-
ent mechanism often have substantially different clinical
properties. One example (among many) is the difference
between vinca alkaloid antimicrotubule agents [55]. Two
novel small molecules - b-AP15 and RA190 - that are pro-
posed to kill cancer cells by inhibiting the proteasome
have been reported. B-AP15 simultaneously inhibits the
proteasome-associated deubiquitinating enzymes UchL5
and Usp14, whereas RA190 binds and inhibits the ubiqui-
tin receptor subunit Rpn13 [56,57]. In addition, other
targets, including Rpn11, the Rpt AAA ATPases, and
the pockets in the 20S to which the Rpt subunits dock,should be drugable with small molecules. Although a
high-throughput screening (HTS) assay that monitors as-
sembly of 19S RPs with 20S cylinders has not been re-
ported, an HTS assay for identifying inhibitors of Rpn11
and the Rpt enzymes was originally developed at Proteolix
[58] and refined in my laboratory [59]. Implementation of
our method allowed us to identify small molecules that
are candidate Rpn11 inhibitors. It remains to be seen
whether suitable molecules that inhibit the Rpt ATPases
can be identified by this approach. A great deal of work
needs to be done to develop clinical-grade molecules that
inhibit other aspects of proteasome function, but the suc-
cess of bortezomib and carfilzomib provides motivation
for pursuing these targets.
The fourth approach is to combine proteasome inhibi-
tors with other agents that influence PQC. This includes
inhibitors of Hsp90 and HDAC6, as well as agents dis-
cussed in the next paragraph. To date, several efforts
registered at clinicaltrials.gov have been initiated and/or
completed. Whereas the data for Hsp90 plus proteasome
inhibitor combinations have yet to yield an obvious clin-
ical benefit, the HDAC inhibitor panobinostat in com-
bination with bortezomib and dexamethasone yielded a
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vival compared to the control arm lacking panobinostat
[60]. Ironically, the most successful combination with
proteasome inhibitors has been the immunomodula-
tory agent lenalidomide, even though, superficially, it
would appear that proteasome inhibitors and lenalido-
mide should counteract each other, because lenalidomide
appears to work by activating degradation of the IKZF1
and IKZ3 transcription factors [61-63].
A fifth approach to addressing the proteotoxic crisis
hypothesis is to identify other suitable targets in the UPS
besides the 26S proteasome. Multiple efforts have been
initiated in this direction. There have been many pro-
grams to generate inhibitors of E3 ubiquitin ligases and
deubiquitinating enzymes, but these are not covered
here because in all of these cases, the intention has been
to prevent the degradation of tumor suppressor proteins
(for example, p27 or p53) or accelerate the degradation
of proto-oncoproteins (for example, Hdm2), and hence
these efforts do not fit in the ‘proteotoxic crisis’ category
elaborated on here.
In addition, there have been attempts to target more
broadly acting components of the UPS, including the
Nedd8 activating enzyme (NAE) [64]. Nedd8 is an
ubiquitin-like protein that is conjugated to cullins fol-
lowing its activation by NAE. NAE-dependent conjuga-
tion of Nedd8 switches on the activity of cullin-RING
ubiquitin ligases (CRLs), which number in the hundreds
and play important roles in cell cycle control, signaling,
and DNA damage, but have not been extensively linked
to PQC. Thus, an NAE inhibitor is also not predicted to
kill cancer cells by inducing proteotoxic crisis. The closely
related ubiquitin-activating enzyme (UAE), on the other
hand, is required for all ubiquitin-dependent degradation
by the proteasome as well as non-degradative signaling by
monoubiquitination, and thus its inhibition is likely to
have very broad effects, including blockade of PQC and
induction of proteotoxicity. Two different inhibitors of
UAE have been reported - PYR41 [65] and the adenine
sulfamate analog Compound I [66]. PYR-41 blocks accu-
mulation of ubiquitin conjugates, promotes accumulation
of p53, and preferentially kills transformed cells that ex-
press p53. However, the specificity of this molecule for
UAE versus other cysteine-based enzymes was not evalu-
ated in depth. Meanwhile, Millennium Pharmaceuticals’
Compound I blocks formation of E2-ubiquitin thioesters
and polyubiquitin conjugates in cells, but its effects on cell
viability were not reported. However, clinicaltrials.gov lists
an active phase 1 trial sponsored by Millennium for the
ubiquitin-activating enzyme inhibitor MLN7243 [67]. Be-
cause there are no publications yet that name this mol-
ecule, it is not known how it relates to Compound I.
Other targets that have been pursued in the broader
arena of PQC include the transmembrane signalingenzymes IRE1 [68-70] and PERK [71-73]. Neither of these
proteins is a UPS component per se, but I discuss them
here briefly because they are involved in a regulatory re-
sponse that is intimately connected to the UPS. Both
PERK and IRE1 are transmembrane proteins of the ER
membrane that contain cytosolic protein kinase domains.
IRE1 also contains a cytosolic endoribonuclease activity.
Both of these proteins sense misfolded proteins in the ER
and employ their kinase (PERK) or nuclease (IRE1) do-
mains to signal the presence of unfolded proteins in the
ER to the cytosol and nucleus. This results in induction of
the UPR, leading to downregulation of general translation
and upregulation of proteins that increase the biosynthetic
capacity of the ER. Inhibition of PERK or IRE1 thus has
potential to induce a proteotoxic crisis by preventing the
UPR in cancers such as MM that may rely on the UPR for
survival. Indeed, both PERK [73] and IRE1 [70] inhibitors
are cytotoxic to cancer cells and have shown activity in
multiple myeloma xenograft models. However, the PERK
inhibitor exhibited pancreatic toxicity, which may compli-
cate its clinical development. There has yet to be a human
clinical trial that targets either enzyme.
Several years ago, my laboratory embarked on the path
of identifying a new target in PQC. The criteria we set
forth was that the ideal target should be: (i) drugable
(that is, an enzyme); (ii) a key player in PQC; and
(iii) mutated, amplified, hyperactivated, or overexpressed
in some cancers, consistent with the idea that its activity
contributes to the cancer lifestyle. To this, we added the
optional criterion that an optimal target would be re-
quired for both NF-κB activation and ERAD. In surveying
the UPS landscape we settled on the AAA ATPase p97,
also known as valosin-containing protein (VCP). At
that time, p97 was well-known to be required for ERAD
[74] and had been linked to NF-κB regulation by co-
immunoprecipitation studies [75]. Recent functional
studies have confirmed the significance of the physical in-
teractions [76]. p97 was also known to be overexpressed
in multiple cancers [77-83], pointing to a possible addic-
tion [84].
p97: a key player in protein quality control
As described at the outset of this article, substrates modi-
fied with ubiquitin chains are bound and degraded by the
26S proteasome. In many cases, the proteasome does not
require assistance [85]. However, there are some ubiquitin-
conjugated substrates that the 26S proteasome is unable to
degrade without additional help from p97. p97 is a homo-
hexamer that associates with different adaptors to pro-
mote degradation of a subset of UPS targets. In particular,
p97 activity has been linked to PQC pathways (Figure 5).
p97 functions downstream of ubiquitin ligases and in
conjunction with the 26S proteasome, helping to extract
ubiquitinated substrates from cellular structures (Figure 5
Figure 5. Roles of p97 in protein quality control. Upper left: p97 extracts unfolded or misassembled secretory and membrane proteins from
the ER. Concomitant with extraction, substrates are conjugated with ubiquitin (green circle with U). Upper right: ribosomes that stall during
translation are disassembled into 40S +60S by an upstream factor. The ubiquitin-conjugated nascent chain remains attached to tRNA and
passes through the exit tunnel (dotted segment). p97 recognizes these complexes and releases the nascent chain from the ribosome.
Lower left and right: protein and protein-RNA aggregates require p97 for metabolism. p97 may either disassemble aggregates so that the
proteasome can degrade them (lower left), or the aggregates can be packaged into autophagosomes (lower right) for delivery to the
lysosome. p97 is required for an undetermined step in autophagosome maturation.
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left) so that they can be threaded into the proteasome for
degradation [86,87]. The requirement for p97 in the UPS
is best understood in the context of ERAD. p97 promotes
retrotranslocation of proteasome substrates across the ER
membrane so that they can gain access to the proteasome
[74]. Thus, in the absence of p97 activity, ERAD substrates
accumulate in the ER. It is thought that all ERAD sub-
strates depend on p97 for their degradation [88]. However,
a great deal remains unknown about p97. For example, it
is not known why some nuclear and cytosolic substrates
of the UPS depend on p97 for their degradation and
others do not. In some cases like ERAD and degradation
of RNA polymerase II stalled at sites of DNA damage
[89], p97 is required to extract the substrate from a larger
biological structure that may impede access of the 26S
proteasome. In other cases such as the model substrate
ubiquitin-GFP, p97 may initiate unfolding to reveal an
unstructured region that can be grasped by the 26S pro-
teasome [90]. I would like to suggest that substrate de-
pendence on p97 defines a continuum, with the degree
of dependence inversely proportional to the statistical
probability that the 26S proteasome ATPases are suffi-
cient to capture, unfold and translocate a substrate into
the 20S cavity before it dissociates. An additional mys-
tery that remains to be solved is, how does p97 recognize
its nuclear and cytosolic substrates and process them for
degradation?Despite the relative paucity of insight into the mechan-
ism of p97 function, considerable progress has been
made recently in linking p97 to various substrates and
quality control processes within the UPS. In addition to
ERAD (Figure 5 upper left), it has been shown that p97 par-
ticipates in multiple PQC pathways, including ribosome-
associated degradation (RAD; Figure 5 upper right) of
peptides produced from defective mRNAs [91-93] and
clearance of ribonucleoprotein stress granules [94]. The
connection between p97 and autophagy [95-97] may be of
particular significance, because cells can adapt to genetic
suppression of proteasome function by upregulating au-
tophagy [98] - an option that might not be available in a
cell exposed to a p97 inhibitor. Taken together, these data
implicate p97 as a critical player central to protein homeo-
stasis. In addition, p97 has been linked to numerous other
degradation pathways in the UPS. For a more thorough
discussion of the PQC and non-PQC functions of p97,
please consult [86,87].
Identification of p97 ATPase inhibitors
Cancer cells rapidly activate caspase and undergo cell
death upon depletion of p97 [99,100]. However, primary
rat hepatocytes [101] and mouse skeletal muscle cells
[102] do not undergo apoptosis upon p97 depletion,
raising the possibility that p97 inhibitors might be more
cytotoxic to cancer cells than normal cells. To address
the potential of p97 as a drug target in oncology, we and
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p97 ATPase activity (Figure 6). So far, the inhibitors that
exhibit the best combination of biochemical and cell-
based potency and specificity are ML240 and ML241
[103] (Figure 6G,H), which are based on the quinazo-
line scaffold DBeQ [100] (Figure 6D), and NMS873 [99]
(Figure 6J). These are described in more detail below. In
addition a number of other inhibitors have been reported,
including Eer1 [104] (Figure 6A), 2-anilino-4-aryl-1,3-
thiazoles (Figure 6B,C) [105,106], xanthohumol [107]
(Figure 6E), the tyrosine kinase inhibitor sorafenib
[108] (Figure 6F), the covalent inhibitor NMS859 [99]
(Figure 6I), KUS69 [109] (the most potent of five
closely related KUS compounds), rheoemodin (Figure 6L),
1-hydroxydehydroherbarin (Figure 6M), phomapyrroli-
done A [110] (Figure 6N), and Syk inhibitor III [111].
To screen for p97 inhibitors, we developed an assay to
monitor the action of p97 in cells by exploiting the obser-
vation that proteins fused to the carboxyl terminus of ubi-
quitin are degraded by the ‘ubiquitin fusion degradation’
(UFD) pathway, of which p97 is a component [112]. Our
assay relies on accumulation of UbG76V-GFP using the rap-
idly reversible proteasome inhibitor MG132 [113]. MG132
is then removed and the decay of the pre-accumulatedFigure 6. Structures of p97 inhibitors. The inhibitors are as indicated in
literature. Myriad-19 is similar to Myriad-12 except that it lacks the chlorine
KUS69 is the most potent of a series of five structurally related compoundsUbG76V-GFP signal is monitored in the presence of the
protein synthesis inhibitor cycloheximide. To evaluate spe-
cificity, we monitor degradation of an ODD-luciferase
chimera (ODD is the oxygen-dependent degradation do-
main from HIF-1α) [114]. p97 is not required for ODD-
luciferase degradation, and hence p97 inhibitors stabilize
UbG76V-GFP but not ODD-luciferase [111]. By this criter-
ion, DBeQ was identified as a selective p97 inhibitor and is
the first selective inhibitor of an AAA ATPase activity.
Structure-activity relationships analysis of DBeQ iden-
tified the more potent derviatives ML240 and ML241
(Figure 6G,H) [103]. Whereas all three compounds
stabilize UbG76V-GFP, cause accumulation of ubiquitin
conjugates, and inhibit degradation of an ERAD substrate,
DBeQ and ML240 also cause accumulation of LC3-II
(indicative of a block to autophagy) and induce rapid
cell death (with modest selectivity for transformed cells),
whereas ML241 does not. The basis for this different be-
havior remains unclear.
NMS859 and NMS873 (Figure 6I,J), arose from a high-
throughput screen for p97 ATPase inhibitors followed by
a structure-activity relationships analysis [99,115]. Of par-
ticular interest is NMS873, which is a reversible, allosteric
inhibitor of p97 ATPase. It is the most potent p97 ATPasethe figure. Inhibitors are listed in order of their first report in the
atom. ML080 behaves essentially the same as the Myriad compounds.
.
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30 nM. Similar to DBeQ, NMS873 impinges on both the
UPS and autophagy, and is cytotoxic across a broad range
of cancer cell lines. Interestingly, unlike proteasome inhib-
itors, it is not more cytotoxic to MM cells than to other
cancer cells. Its relative cytotoxicity in non-transformed
cells was not reported.
p97 inhibitors and the proteasome recovery
pathway
When the proteasome is inhibited, cells respond by upreg-
ulating the transcription of genes that encode proteasome
subunits. This regulation depends on the transcription
factor Nrf1/NFE2L1 [116,117]. We and others [118-120]
have investigated the mechanism by which Nrf1 is acti-
vated (Figure 7). Nrf1 is initially synthesized as a type II
transmembrane protein of the ER, such that a very small
segment of the amino terminus faces the cytosol, and the
bulk of the protein is in the ER lumen. However, this spe-
cies is a very short-lived intermediate, and the carboxy-
terminal domain of Nrf1 is quickly retrotranslocated to
the cytosolic face of the ER in a manner that depends
upon p97. Under normal circumstances, retrotransloca-
tion of Nrf1 is coupled to its degradation by the prote-
asome, so that active Nrf1 does not accumulate. However,
if the proteasome is inhibited, the retrotranslocated Nrf1
is cleaved after Trp103 to release a carboxy-terminal frag-
ment, p110, which travels to the nucleus and activates
gene expression [121]. When p97 is inhibited, Nrf1 is notFigure 7. Mechanism of Nrf1 activation. Upon completion of synthesis,
extracts Nrf1 from the ER, and it is then fed to the proteasome (2). Because
degradation, there is very little accumulation of Nrf1 at steady-state. In cells
degradation of Nrf1 become kinetically uncoupled. Accumulation of Nrf1 o
by an unknown protease (5), which releases a soluble 110 kDa fragment that
encode proteasome subunits. PSM: proteasome components.retrotranslocated, and the carboxy-terminal domain, which
contains the sequences that mediate gene activation, re-
mains in the ER lumen. Consequently, simultaneous inhib-
ition of p97 and the proteasome prevents formation of
p110 and activation of proteasome gene expression that
normally follows inhibition of the proteasome. This could
explain a recent observation that proteasome and p97
inhibitors exhibit synergistic activity towards MM cells
in vitro [122]. Thus, it may be possible to control the rate
of recovery of proteasome activity by combining an irre-
versible proteasome inhibitor like carfilzomib with a p97
inhibitor. The protease that cleaves after Trp103 is in dis-
pute [118,120]. Inhibition of this processing step is also a
potentially interesting target, because a non-cleavable mu-
tant of Nrf1 cannot be activated upon inhibition of the
proteasome [118].
PQC inhibitors and cancer therapy
To explore further the clinical potential of ML240
and ML241, as well as a small-molecule scaffold that
inhibits both Rpn11 and the Csn5 subunit of the COP9-
signalosome complex (not discussed here), my partners
and I launched Cleave Biosciences. Cleave has made
rapid progress on the ML240 scaffold, and the deriva-
tive CB-5083 recently entered human phase I trials in
MM and solid tumors [123].
It remains to be seen whether cancer cells in their nat-
ural environment are more sensitive than normal cells to
the proteotoxicity induced by UAE and p97 inhibitors,Nrf1 is rapidly directed into the retrotranslocation pathway (1). p97
of the tight coupling between synthesis, retrotranslocation, and
that are deficient in proteasome activity (3), retrotranslocation and
n the cytosolic side of the membrane renders it susceptible to cleavage
translocates to the nucleus and activates transcription of genes that
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can be achieved with an acceptable side effect profile.
With UAE and p97 inhibitors now in the clinic, we
should not have to wait much longer for an answer.
Prospects for establishing the proteotoxic
principle in tumor therapy
The proteotoxic crisis hypothesis suggests the attractive
prospect that it may be possible to attack a broad range
of human cancers by taking advantage of their presumed
heightened dependence on PQC pathways. This height-
ened dependency is predicted to arise from the very mu-
tations and genomic instabilities that fuel development
of the cancer in the first place. The clinical experience
to date with the proteasome inhibitor bortezomib on the
one hand suggests that the proteotoxic crisis hypothesis
may apply to at least some cancers, but on the other
hand may not be broadly applicable. However, the limited
efficacy of bortezomib in solid tumors may be due to the
pharmacology of the existing proteasome inhibitors and
the existence of a cellular homeostatic mechanism that en-
ables a compensatory response to proteasome inhibition,
rather than a problem with the proteotoxic crisis hypoth-
esis per se. New approaches to inhibiting the proteasome
or other UPS targets like UAE and p97 may provide a
more salient test of the hypothesis that cancer cells,
broadly speaking, are more dependent on PQC pathways
than normal cells and thus should be selectively vulnerable
to inhibition of PQC.
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